335 related articles for article (PubMed ID: 31115592)
1. Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis.
Zhou W; Liu Y; Guo X; Yang H; Xu Y; Geng D
Osteoporos Int; 2019 Aug; 30(8):1581-1589. PubMed ID: 31115592
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy of zoledronic acid combined with calcitriol in elderly patients receiving total hip arthroplasty or hemiarthroplasty for osteoporotic femoral neck fracture.
Zhu K; Zhang J; Zhang C; Zhao Z; Gao J; Li X; Xia X; Xu X; Zhang T; Guan J
Osteoporos Int; 2021 Mar; 32(3):559-564. PubMed ID: 32989470
[TBL] [Abstract][Full Text] [Related]
3. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
[TBL] [Abstract][Full Text] [Related]
4. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
Koldkjær Sølling AS; Harsløf T; Langdahl B
Osteoporos Int; 2019 May; 30(5):995-1002. PubMed ID: 30656367
[TBL] [Abstract][Full Text] [Related]
5. Efficiency of Zoledronic Acid in Inhibiting Accelerated Periprosthetic Bone Loss After Cementless Total Hip Arthroplasty in Osteoporotic Patients: A Prospective, Cohort Study.
Fu GT; Lin LJ; Sheng PY; Li CC; Zhang JX; Shen J; Liu S; Xue YL; Lin SP; Wang K; Zheng QJ; Ding Y
Orthop Surg; 2019 Aug; 11(4):653-663. PubMed ID: 31456320
[TBL] [Abstract][Full Text] [Related]
6. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
Mori Y; Kasai H; Ose A; Serada M; Ishiguro M; Shiraki M; Tanigawara Y
Osteoporos Int; 2018 May; 29(5):1155-1163. PubMed ID: 29423715
[TBL] [Abstract][Full Text] [Related]
7. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
8. A long-lasting bisphosphonate partially protects periprosthetic bone, but does not enhance initial stability of uncemented femoral stems: A randomized placebo-controlled trial of women undergoing total hip arthroplasty.
Aro E; Moritz N; Mattila K; Aro HT
J Biomech; 2018 Jun; 75():35-45. PubMed ID: 29747966
[TBL] [Abstract][Full Text] [Related]
9. Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial.
Huang TW; Wang CJ; Shih HN; Chang Y; Huang KC; Peng KT; Lee MS
BMC Musculoskelet Disord; 2017 May; 18(1):209. PubMed ID: 28532408
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal changes in bone mineral density and trabecular bone score following yearly zoledronic acid infusion in postmenopausal osteoporosis-a retrospective-prospective study from southern India.
Sooragonda B; Cherian KE; Jebasingh FK; Dasgupta R; Asha HS; Kapoor N; Thomas N; Paul TV
Arch Osteoporos; 2019 Jul; 14(1):79. PubMed ID: 31321603
[TBL] [Abstract][Full Text] [Related]
11. Effect of zoledronic acid on vertebral marrow adiposity in postmenopausal osteoporosis assessed by MR spectroscopy.
Yang Y; Luo X; Yan F; Jiang Z; Li Y; Fang C; Shen J
Skeletal Radiol; 2015 Oct; 44(10):1499-505. PubMed ID: 26130070
[TBL] [Abstract][Full Text] [Related]
12. [Bone Remodelling in the Proximal Femur after Uncemented Total Hip Arthroplasty in Patients with Osteoporosis].
Lacko M; Schreierová D; Čellár R; Vaško G
Acta Chir Orthop Traumatol Cech; 2015; 82(6):430-6. PubMed ID: 26787184
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid combined with percutaneous kyphoplasty in the treatment of osteoporotic compression fracture in a single T12 or L1 vertebral body in postmenopausal women.
Zhang J; Zhang T; Xu X; Cai Q; Zhao D
Osteoporos Int; 2019 Jul; 30(7):1475-1480. PubMed ID: 30976888
[TBL] [Abstract][Full Text] [Related]
14. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a Disease-Drug Trial Model for Postmenopausal Osteoporosis: A Zoledronic Acid Case Study.
Lien YTK; Madrasi K; Samant S; Kim MJ; Li F; Li L; Wang Y; Schmidt S
J Clin Pharmacol; 2020 Dec; 60 Suppl 2():S86-S102. PubMed ID: 33274518
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
Catalano A; Morabito N; Basile G; Brancatelli S; Cucinotta D; Lasco A
J Clin Endocrinol Metab; 2013 May; 98(5):1911-5. PubMed ID: 23596142
[TBL] [Abstract][Full Text] [Related]
17. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
[TBL] [Abstract][Full Text] [Related]
18. The use of bone turnover markers for monitoring the treatment of osteoporosis in postmenopausal females undergoing total knee arthroplasty: a prospective randomized study.
Ma R; Wu M; Li Y; Wang J; Yang P; Chen Y; Wang W; Song J; Wang K
J Orthop Surg Res; 2021 Mar; 16(1):195. PubMed ID: 33731168
[TBL] [Abstract][Full Text] [Related]
19. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
[TBL] [Abstract][Full Text] [Related]
20. [Effects of denosumab on bone mineral density around proximal femoral prosthesis after total hip replacement in postmenopausal osteoporotic patients].
Ning WH; Xu GZ; Wang JW
Zhongguo Gu Shang; 2023 Nov; 36(11):1041-5. PubMed ID: 38012872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
